The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $1.46

Today's change+0.15 +11.45%
Updated June 22 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $1.46

Today's change+0.15 +11.45%
Updated June 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc up sharply

Merrimack Pharmaceuticals Inc closed up sharply Thursday, rallying (U.S.)$0.15 or 11.45% to (U.S.)$1.46. Over the last five days, shares have gained 23.73%, but are down 64.22% for the last year to date. Shares have underperformed the S&P 500 by 93.19% during the last year.

Key company metrics

  • Open(U.S.) $1.32
  • Previous close(U.S.) $1.31
  • High(U.S.) $1.50
  • Low(U.S.) $1.29
  • Bid / Ask(U.S.) $1.43 / (U.S.) $1.48
  • YTD % change-64.22%
  • Volume5,365,076
  • Average volume (10-day)5,236,221
  • Average volume (1-month)4,450,201
  • Average volume (3-month)2,719,945
  • 52-week range(U.S.) $1.13 to (U.S.) $6.79
  • Beta1.95
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.10
Updated June 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-117.13%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.47%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue--612834
Total other revenue--------
Total revenue0612834
Gross profit--582732
Total cost of revenue--312
Total operating expense27885264
Selling / general / administrative6241821
Research & development22553241
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--51--
Other operating expenses, total--------
Operating income-27-26-24-30
Interest income (expense), net non-operating-2-7-7-21
Gain (loss) on sale of assets--------
Other--------
Income before tax-29-34-30-51
Income after tax-29-34-30-51
Income tax, total--------
Net income-30-32-30-51
Total adjustments to net income--------
Net income before extra. items-29-32-30-51
Minority interest0100
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-29-32-30-51
Inc. avail. to common incl. extra. items-30-32-30-51
Diluted net income-30-32-30-51
Dilution adjustment000--
Diluted weighted average shares131130129126
Diluted EPS excluding extraordinary itemsvalue per share-0.22-0.25-0.23-0.40
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.22-0.21-0.23-0.40